Dhaval comes to Aerpio with 15 years of experience in marketing, medical affairs and clinical development. In addition, he brings hands-on pre- and post-launch experience in the retina therapeutic space. Prior to joining Aerpio, Dhaval worked at ThromboGenics, Inc. where he held roles in marketing and medical affairs. At ThromboGenics, he was an integral member of the pre-launch team and led all market development efforts. He also led the team that achieved FDA approval of ocriplasmin (Jetrea™) for the treatment of symptomatic VMA. During this time, he worked closely with and developed strong relationships with many preeminent retinal physicians. Previously, Dhaval worked at Onyx Pharmaceuticals, where he was integral in the early development of sorafenib (Nexavar®) for thyroid cancer. Dhaval obtained his PharmD from and completed his postdoctoral fellowship at Rutgers University.